tildrakizumab monoclonal antibody designed treatment immunologically mediated inflammatory disorders
tildrakizumab designed block interleukin cytokine plays important role managing immune system autoimmune disease originally developed scheringplough drug part mercks clinical program following companys acquisition scheringplough
sun pharmaceutical acquired worldwide rights tildrakizumab use human indications merck exchange upfront payment us million upon product approval sun pharmaceutical responsible regulatory activities including subsequent submissions pharmacovigilance post approval studies manufacturing commercialization approved product
march drug phase iii clinical trials plaque psoriasis two trials enroll total nearly patients preliminary results expected june
see also
ustekinumab monoclonal antibody targeting il il used treat plaque psoriasis launched united states brand name stelara
guselkumab another experimental ilspecific monoclonal antibody
references
statement nonproprietary name adopted usan council tildrakizumab american medical association
httpwwwmerckcomlicensingourpartnershipsunpharmapartnershiphtml
httpclinicaltrialsgovctshowncttermschphasefundrank
httpclinicaltrialsgovctshowncttermschphasefundrank
